EURO-ATAXIA
Members work together for people with ataxia. We drive forward research, treatment & best practice; foster & improve contact between researchers/practitioners and people affected by ataxia; promote cooperation between international ataxia organisations, share best practice and raise awareness of ataxia among clinicians, scientists, policy makers and the general public.
Objects
TO RELIEVE THOSE PERSONS AFFECTED BY ATAXIA
Latest income
£23k
Latest spending
£19k
Registered
2012
Policies the charity declares
- Internal charity financial controls policy and procedures
- Trustee conflicts of interest policy and procedures
- Trustee expenses policy and procedures
From the charity’s annual return (Part A, self-declared)
Self-declared on the annual return for the financial year ending 30/08/2024
- Grant-making is its main activity
Self-declared on the annual return for the financial year ending 30/08/2023
- Volunteers: 10
Annual return filing dates (Charity Commission record)
Of its last 5 annual returns with a recorded received date, 2 were received after the due date: year ending 30/08/2024 (received 21/07/2025, 21 days after the 30/06/2025 due date); year ending 30/08/2023 (received 19/09/2024, 81 days after the 30/06/2024 due date).
Trustees
- Andreas Nadkechair
- Bart Johan Peter Schuman
- John Gerbild
- Juan-Carlos Baiges-Salvado
- SUSAN Jane MILLMAN
- Susie Norbury
- Vasileios Karatzias
Income and spending
| Financial year end | Income | Spending |
|---|---|---|
| 30/08/2025 | £23k | £19k |
| 30/08/2024 | £27k | £26k |
| 30/08/2023 | £20k | £9k |
| 31/08/2022 | £8k | £6k |
| 31/08/2021 | £6k | £5k |
Government & lottery funding
| Funder | Date | Amount | Purpose |
|---|---|---|---|
| UK government | 18/05/2023 | £10k | Accelerating drug repurposing for rare neurological, neurometabolic and neuromuscular disorders by exploiting SIMilarities in clinical and molecular PATHology |
| UK government | 18/05/2023 | £5k | Accelerating drug repurposing for rare neurological, neurometabolic and neuromuscular disorders by exploiting SIMilarities in clinical and molecular PATHology |